UNSPSC 51431904: Candesartan cilexetil

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C33H34N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R85M2X0D68, chemically known as 1h-benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)- but more generally known as candesartan cilexetil, which bears US NIH Compound Identifier 2540.

UNSPSC 51431904 Candesartan cilexetil is a Commodity code that describes a specific antihypertensive pharmaceutical product, but state and local procurement activity tagged to this code shows a material scope mismatch. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB 26P00188) for Tampa Fire Rescue in April 2026, specifying four distinct emergency-response drugs — Labetalol HCI, Epinephrine, Adenosine, and Diltiazem — none of which are Candesartan cilexetil. The solicitation required medications with nine-month minimum shelf life, delivery within ten calendar days of order, and a 365-day material-defect warranty with vendor pickup of expired stock. All medications required Safety Data Sheets compliant with OSHA Hazard Communication Standards and accessibility conformance documentation per WCAG 2.2 and Section 508 standards.

The City of Tampa was the sole issuing body identified in recent opportunities under this code; this single procurement does not establish a pattern of activity or repeat buyer status. The estimated contract value was $40,000.00 with a one-year term and two optional one-year renewals, plus up to three unilateral 30-day extensions. The solicitation carried a 5 percent bid discount (not to exceed $10,000) for Small Local Business Enterprise participation and required vendors to submit comprehensive SLBE subcontracting documentation. The code shows minimal relevant recent activity; the single opportunity tagged to Candesartan cilexetil was actually a multi-product emergency pharmaceutical procurement serving a specific operational need rather than ongoing commodity purchase of this single drug formulation.